TScan Therapeutics, Inc.
TCRX
$1.82
$0.084.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.96M | 4.42M | 2.82M | 9.36M | 12.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.96M | 4.42M | 2.82M | 9.36M | 12.20M |
| Cost of Revenue | 15.53M | 9.78M | 4.85M | 15.13M | 11.60M |
| Gross Profit | -8.57M | -5.36M | -2.03M | -5.76M | 596.00K |
| SG&A Expenses | 33.16M | 31.84M | 30.29M | 28.43M | 26.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 151.20M | 144.12M | 137.64M | 128.83M | 123.79M |
| Operating Income | -144.24M | -139.70M | -134.82M | -119.47M | -111.59M |
| Income Before Tax | -136.78M | -131.48M | -127.50M | -111.30M | -104.41M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -136.78 | -131.48 | -127.50 | -111.30 | -104.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.78M | -131.48M | -127.50M | -111.30M | -104.41M |
| EBIT | -144.24M | -139.70M | -134.82M | -119.47M | -111.59M |
| EBITDA | -141.12M | -136.17M | -130.71M | -114.79M | -106.66M |
| EPS Basic | -2.45 | -2.39 | -2.42 | -2.20 | -2.12 |
| Normalized Basic EPS | -1.52 | -1.48 | -1.50 | -1.37 | -1.32 |
| EPS Diluted | -2.45 | -2.39 | -2.42 | -2.20 | -2.12 |
| Normalized Diluted EPS | -1.52 | -1.48 | -1.50 | -1.37 | -1.32 |
| Average Basic Shares Outstanding | 223.28M | 219.47M | 210.78M | 202.02M | 196.49M |
| Average Diluted Shares Outstanding | 223.28M | 219.47M | 210.78M | 202.02M | 196.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |